lutetium zadavotide guraxetan (PNT2002) / Lantheus 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lutetium zadavotide guraxetan (PNT2002) / Lantheus
2021-002641-15: To investigate safety and effectiveness of PSMA directed [177-Lu]-PNT2002, an investigational agent for treatment of patients with mCRPC

Not yet recruiting
3
390
Europe
177Lu-PNT2002, 68Ga-PSMA-11 prepared using PSMA-11 sterile kit, Abiraterone, Enzalutamide, 177Lu-PNT2002, Solution for injection, Film-coated tablet, Zytiga, Xtandi, GalliaPharm
Point BioPharma Inc., Point BioPharma
Metastatic Castrate Resistant Prostate Cancer (mCRPC), Prostate cancer, Diseases [C] - Cancer [C04]
 
 
SPLASH, NCT04647526: Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

Checkmark Efficacy and safety data from SPLASH trial for mCRPC at ESMO 2022
Sep 2022 - Sep 2022: Efficacy and safety data from SPLASH trial for mCRPC at ESMO 2022
Checkmark Efficacy and safety data from the lead-in cohort of the SPLASH trial in mCRPC
Sep 2022 - Sep 2022: Efficacy and safety data from the lead-in cohort of the SPLASH trial in mCRPC
Active, not recruiting
3
415
Europe, Canada, US
[Lu-177]-PNT2002, [Lu-177]-PSMA-I&T, Abiraterone, Enzalutamide
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Metastatic Castration-Resistant Prostate Cancer
11/23
03/28
ROADSTER, NCT05230251: Radioligand fOr locAl raDiorecurrent proStaTe cancER

Active, not recruiting
2
12
Canada
177Lu-PNT2002, [Lu-177]-PNT2002 Injection, High Dose Radiation
Glenn Bauman, London Health Sciences Foundation
Prostate Cancer
09/23
12/24
LUNAR, NCT05496959: 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The Study

Active, not recruiting
2
93
US
Lutetium Lu-177 PNT2002, 177Lu-labeled PNT2002, 177Lu-PNT2002, [Lu-177]-PNT2002, [Lu-177]-PSMA-I and T, Lu177-PNT2002, Lutetium Lu-177-PNT2002, Quality-of-Life Assessment, Quality of Life Assessment, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
Jonsson Comprehensive Cancer Center, POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
09/32
09/33
NCT06322576: 177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma

Not yet recruiting
2
10
US
177Lu-PNT2002, 177Lu PSMA
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Adenoid Cystic Carcinoma Research Foundation, Progenics Pharmaceuticals, Inc.
Adenoid Cystic Carcinoma
03/30
02/35
NCT04886986: Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer

Suspended
1/2
48
US
225Ac-J591, 177Lu-PSMA-I&T, 177Lu-PNT2002, 68Ga-PSMA-11, 68Ga-PSMA-HBED-CC
Weill Medical College of Cornell University, POINT Biopharma
Prostate Cancer
12/25
12/27
NCT06361810: PSMA Therapy and Immunotherapy in Kidney Cancer

Not yet recruiting
1/2
37
NA
Pembrolizumab, Keytruda, 177Lu-PNT2002, 177Lu-PSMA I&T, (F-18)-DCFPyL, Pylarify
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Merck Sharp & Dohme LLC, Lantheus Medical Imaging
Metastatic Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
01/31
01/32
NCT06033001: Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Temporarily Not Available
N/A
US
[Lu-177]-PNT2002
Lantheus Medical Imaging, Eli Lilly and Company
Castration-Resistant Prostatic Cancer
 
 

Download Options